Familial Mediterranean Fever with a Single MEFV Mutation: Where is the Second Hit?
Overview
Authors
Affiliations
Objective: Familial Mediterranean fever (FMF) has traditionally been considered an autosomal-recessive disease; however, it has been observed that a substantial number of patients with clinical FMF possess only 1 demonstrable MEFV mutation. The purpose of this study was to perform an extensive search for a second MEFV mutation in 46 patients diagnosed clinically as having FMF and carrying only 1 high-penetrance FMF mutation.
Methods: MEFV and other candidate genes were sequenced by standard capillary electrophoresis. In 10 patients, the entire 15-kb MEFV genomic region was resequenced using hybridization-based chip technology. MEFV gene expression levels were determined by quantitative reverse transcription-polymerase chain reaction. Pyrin protein levels were examined by Western blotting.
Results: A second MEFV mutation was not identified in any of the patients who were screened. Haplotype analysis did not identify a common haplotype that might be associated with the transmission of a second FMF allele. Western blots did not demonstrate a significant difference in pyrin levels between patients with a single mutation and those with a double mutation; however, FMF patients of both types showed higher protein expression as compared with controls and with non-FMF patients with active inflammation. Screening of genes encoding pyrin-interacting proteins identified rare mutations in a small number of patients, suggesting the possibility of digenic inheritance.
Conclusion: Our data underscore the existence of a significant subset of FMF patients who are carriers of only 1 MEFV mutation and demonstrate that complete MEFV sequencing is not likely to yield a second mutation. Screening for the set of the most common mutations and detection of a single mutation appears to be sufficient in the presence of clinical symptoms for the diagnosis of FMF and the initiation of a trial of colchicine.
Terzi M, Ozcan O, Kimyon G, Okuyan H, Arpaci A, Dogan S Clin Rheumatol. 2025; .
PMID: 39934489 DOI: 10.1007/s10067-025-07359-2.
Durmus S, Gelisgen R, Hajiyeva R, Adrovic A, Yildiz M, Yucesan E BMJ Paediatr Open. 2025; 9(1.
PMID: 39779193 PMC: 11749570. DOI: 10.1136/bmjpo-2024-003064.
The journey of MEFV heterozygous children: with or without colchicine.
Cakan M, Alkaya A, Koru L, Oksel B, Akgun O, Tunce E Eur J Pediatr. 2024; 184(1):40.
PMID: 39581919 DOI: 10.1007/s00431-024-05887-8.
Elhani I, Backes S, Kallinich T, Amaryan G, Belot A, Berendes R RMD Open. 2024; 10(4).
PMID: 39581688 PMC: 11590780. DOI: 10.1136/rmdopen-2024-004677.
Recurrent Pericarditis and Paradigm Shift in Cardiovascular Imaging and Targeted Therapeutics.
Karmali R, Kafil T, Bayat A, Honnekeri B, Badwan O, Berglund F JACC Adv. 2024; 3(9):101194.
PMID: 39372451 PMC: 11451297. DOI: 10.1016/j.jacadv.2024.101194.